Developer docs
API playgroundTry for free, no card

Search company profiles

Celling Biosciences

Full company profile

uuid000a5in

Namestring
Celling Biosciences
Legal namestring
Celling Biosciences
Company typeenum
Private
Founded yearint
2005
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine devices, autologous cell therapy, bone marrow concentration, platelet-rich plasma systems, point-of-care processing
Industry4 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Medical Equipment and Supplies Manufacturing33911
  • Surgical and Medical Instrument Manufacturing339112
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Regenerative Medicine Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Consumable Sales
TypeHardware Sales
Description

Celling Biosciences generates revenue through the sale of medical devices and consumables for autologous cell therapy, including the ART BMC and ART PRP product families, bone marrow aspiration kits, injectable bone void fillers, and spinal hardware products. Products are sold directly to physicians and through distributor networks.

cellingbiosciences.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Quote-based enterprise pricing for medical devices
ModelOtherBilling cadenceMulti-year contract
Notes

Direct sales model with personalized quotes. Contact sales for ART PRP, ART BMC, Solum, and Collection/Delivery products.

cellingbiosciences.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ART (Autologous Regenerative Therapies)
Description

Product portfolio designed for the optimal processing of tissue at the point of care to isolate certain cells for autologous cellular collection. Includes ART PRP Plus, ART PRP 2-Step, ART BMC Plus, and ART BMC systems.

cellingbiosciences.com
+3 more records
Core offering1 text field

Celling Biosciences designs, manufactures, and sells point-of-care medical devices and consumables for autologous cellular therapy. Its core offering is the ART (Autologous Regenerative Therapies) family of bone marrow and platelet concentration systems, supplemented by bone marrow aspiration kits, Cell Probe 360 needles, Solum injectable bone void fillers, and a line of spinal hardware implants, all sold to physicians and healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • The Hernigou aspiration method (basis for Cell Probe 360) obtains 300% more mesenchymal stem cells than traditional aspiration techniques
+3 more records
Product overview1 text field

Celling Biosciences offers a comprehensive portfolio of point-of-care regenerative medicine products organized across three main categories: Tissue Collection (bone marrow aspiration kits), Tissue Concentration (ART PRP and ART BMC systems for concentrating platelets and bone marrow), and Tissue Delivery (Solum bone void fillers and spinal hardware). The ART product family is the company's core platform, featuring the only integrated ultra-filtration system on the market for processing bone marrow, peripheral blood, and growth factors. The portfolio also includes spinal hardware products developed in partnership with SpineSmith for biologics-minded spinal implants. The company has expanded through acquisitions including ThermiGen (aesthetics) and LinkSpine (spinal fusion systems), and recently announced the Cell Probe 360 aspiration needle pending release in 2024.

Product and service14 records
1ART BMC Plus
CategoryBone Marrow Concentration Devices
Description

Bone marrow concentration system featuring an integrated ultra-filtration filter for processing proteins from platelet poor plasma, allowing physicians to select cell concentrate from user-defined portions of the centrifuged stack for the highest recovery of nucleated and progenitor cells at the point of care.

2ART BMC
CategoryBone Marrow Concentration Devices
Description

Single-use sterile bone marrow concentration device that processes autologous bone marrow aspirate into bone marrow concentrate at the point of care, functioning as a miniaturized laboratory with multiple ports to minimize sterile breaks.

3ART PRP Plus
CategoryPlatelet-Rich Plasma Concentration Devices
Description

Platelet-rich plasma concentration system with integrated ultra-filtration that concentrates platelets using nanoporous fibers, reducing 60 mL of whole blood to 3-5 mL of concentrated platelet poor plasma at the point of care.

4ART PRP 2-Step
CategoryPlatelet-Rich Plasma Concentration Devices
Description

Two-step platelet-rich plasma concentration system that processes autologous whole blood at the point of care and recovers the greatest percentage of platelets by allowing manual selection of platelet concentrate from user-defined portions of the centrifuged stack.

5Cell Probe 360
CategoryBone Marrow Aspiration Devices
Description

Patented bone marrow aspiration needle with an integrated valve system based on Dr. Philippe Hernigou's technique that simplifies the procedure by requiring only two syringes throughout, reducing procedure time and limiting sterile breaks.

6Large Volume Bone Marrow Aspiration Kit
CategoryBone Marrow Aspiration Devices
Description

Bone marrow aspiration kit providing all components needed for large volume collection, including 11G aspiration needle, 18G blunt fill needle, syringes, mixing cup, and ACD-A anticoagulant.

7Small Volume Bone Marrow Aspiration Kit
CategoryBone Marrow Aspiration Devices
Description

Bone marrow aspiration kit designed for small volume collection, including seven 10 mL syringes and ACD-A anticoagulant.

8Solum Flow
CategoryBone Void Fillers
Description

Injectable bone void filler composed of an equal ratio of porous hydroxyapatite granules and porcine gelatin, combined at a 1:1 volume ratio with biological fluid, with viscosity that allows easy injection from a needle.

9Solum IV
CategoryBone Void Fillers
Description

Synthetic extracellular matrix biomaterial with an interconnected pore architecture that supports cell adhesion, migration, and proliferation; when combined with bone marrow aspirate, forms a moldable 3D structure that acts as an in vivo bioreactor for bone growth.

10VisuALIF
CategorySpinal Hardware Implants
Description

Two-piece modular lumbar interbody fusion device with modular plating options, anterior open face PEEK component, radiolucent and biocompatible design with radiopaque tantalum markers, and patented design for maximum graft placement.

11IN:C2
CategorySpinal Hardware Implants
Description

Two-piece modular cervical interbody fusion device with modular plating options, multiple screw placement and trajectory choices, and a locking snap-on face plate.

12Corticalink System
CategorySpinal Hardware Implants
Description

Spinal fixation system featuring Quadlead thread design for optimal stability, with self-tapping and self-starting screws, available in 5.5 Corticalink Open System, 5.0 MIS Corticalink, and 5.0 Midline Corticalink variants.

13Facet Link Mini
CategorySpinal Hardware Implants
Description

Facet joint stabilization system that provides robust spinal support and stability through a minimally invasive trans-articular screw approach.

14Cimplicity
CategorySpinal Hardware Implants
Description

Cervical interbody spacer made of biocompatible, radiolucent polyether ether ketone (PEEK) with a large graft area designed to maximize fusion potential.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Celling Biosciences acquired ThermiGen in 2019, expanding into women's health and skin aesthetics markets. ThermiGen is known for its flagship product ThermiRF, which uses temperature to guide non-invasive and minimally-invasive procedures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1SpineSmith Partners
TypeDirect peer
Description

SpineSmith is a partner that has co-developed spinal hardware products with Celling and operates directly in the same spinal fusion and biologics segment as Celling's VisuALIF, IN:C2, Corticalink, and Cimplicity devices.

TypeEmerging player
Description

Regenexx is a regenerative medicine network that delivers autologous cell therapy procedures, including bone marrow concentrate treatments, to patients via affiliated physicians — directly comparable to Celling's clinical use cases in orthopedics and spine.

TypeBroad incumbent
Description

Terumo BCT is a leading cell and blood component processing technology provider. While focused on apheresis and higher-volume cell processing, its technology and commercial reach overlap with Celling's point-of-care concentration space.

TypeBroad incumbent
Description

Stryker is a large diversified medtech player with deep orthopedic, spine, and surgical hardware franchises that overlap with Celling's spinal hardware (LinkSpine) and broader orthopedic cell therapy customers.

TypeDirect peer
Description

Emcyte is a direct competitor in point-of-care autologous PRP and bone marrow concentration systems, offering devices such as the Angel Concentrated Platelet Rich Plasma system that compete head-to-head with Celling's ART PRP and ART BMC families.

TypeBroad incumbent
Description

Zimmer Biomet operates broadly across orthopedics and sports medicine and has invested in regenerative and autologous biologic offerings, making it a broad incumbent comparable to Celling's orthopedic and spine regenerative portfolio.

TypeBroad incumbent
Description

Arthrex is a broad incumbent in orthopedic devices and biologics, offering PRP/BMAC preparation systems used across sports medicine, orthopedics, and spine — competing with Celling across multiple of the same specialties but as part of a much larger portfolio.

TypeDirect peer
Description

Isto Biologics develops autologous and allogeneic orthobiologic solutions including bone marrow concentration devices and bone graft substitutes, directly overlapping with Celling's ART BMC systems and Solum bone void filler products.

TypeEmerging player
Description

LifeNet Health is a regenerative medicine organization offering allograft and cellular therapies used in orthopedics, spine, and wound care — comparable to Celling's regenerative and bone void filler portfolio, though with a different sourcing and distribution model.

10Cesca Therapeutics
TypeEmerging player
Description

Cesca Therapeutics develops autologous cell-based therapies and point-of-care cell processing technologies, making it a comparable emerging player in the autologous regenerative medicine category alongside Celling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celling Biosciences

Regenerative Medicine Medical Devicescellingbiosciences.com

Celling Biosciences firmographics

Firmographics
Name
Celling Biosciences
Legal name
Celling Biosciences
Website
https://cellingbiosciences.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Celling Biosciences industry classification

Industry
Product category
Regenerative Medicine Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (33911), Surgical and Medical Instrument Manufacturing (339112), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Regenerative medicine devices
  • Autologous cell therapy
  • Bone marrow concentration
  • Platelet-rich plasma systems
  • Point-of-care processing

Where Celling Biosciences is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Celling Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device and Consumable Sales: Celling Biosciences generates revenue through the sale of medical devices and consumables for autologous cell therapy, including the ART BMC and ART PRP product families, bone marrow aspiration kits, injectable bone void fillers, and spinal hardware products. Products are sold directly to physicians and through distributor networks.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing for medical devices

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Celling Biosciences product offering

Product offering

Core offering

Celling Biosciences designs, manufactures, and sells point-of-care medical devices and consumables for autologous cellular therapy. Its core offering is the ART (Autologous Regenerative Therapies) family of bone marrow and platelet concentration systems, supplemented by bone marrow aspiration kits, Cell Probe 360 needles, Solum injectable bone void fillers, and a line of spinal hardware implants, all sold to physicians and healthcare providers.

Product overview

Celling Biosciences offers a comprehensive portfolio of point-of-care regenerative medicine products organized across three main categories: Tissue Collection (bone marrow aspiration kits), Tissue Concentration (ART PRP and ART BMC systems for concentrating platelets and bone marrow), and Tissue Delivery (Solum bone void fillers and spinal hardware). The ART product family is the company's core platform, featuring the only integrated ultra-filtration system on the market for processing bone marrow, peripheral blood, and growth factors. The portfolio also includes spinal hardware products developed in partnership with SpineSmith for biologics-minded spinal implants. The company has expanded through acquisitions including ThermiGen (aesthetics) and LinkSpine (spinal fusion systems), and recently announced the Cell Probe 360 aspiration needle pending release in 2024.

Differentiator

Problem solved

Functional benefit

Brands

  • ART (Autologous Regenerative Therapies): Product portfolio designed for the optimal processing of tissue at the point of care to isolate certain cells for autologous cellular collection. Includes ART PRP Plus, ART PRP 2-Step, ART BMC Plus, and ART BMC systems.
  • ThermiGen
  • Cell Probe 360
  • Solum

Products and services

  • ART BMC Plus Bone marrow concentration system featuring an integrated ultra-filtration filter for processing proteins from platelet poor plasma, allowing physicians to select cell concentrate from user-defined portions of the centrifuged stack for the highest recovery of nucleated and progenitor cells at the point of care.
  • ART BMC Single-use sterile bone marrow concentration device that processes autologous bone marrow aspirate into bone marrow concentrate at the point of care, functioning as a miniaturized laboratory with multiple ports to minimize sterile breaks.
  • ART PRP Plus Platelet-rich plasma concentration system with integrated ultra-filtration that concentrates platelets using nanoporous fibers, reducing 60 mL of whole blood to 3-5 mL of concentrated platelet poor plasma at the point of care.
  • ART PRP 2-Step Two-step platelet-rich plasma concentration system that processes autologous whole blood at the point of care and recovers the greatest percentage of platelets by allowing manual selection of platelet concentrate from user-defined portions of the centrifuged stack.
  • Cell Probe 360 Patented bone marrow aspiration needle with an integrated valve system based on Dr. Philippe Hernigou's technique that simplifies the procedure by requiring only two syringes throughout, reducing procedure time and limiting sterile breaks.
  • Large Volume Bone Marrow Aspiration Kit Bone marrow aspiration kit providing all components needed for large volume collection, including 11G aspiration needle, 18G blunt fill needle, syringes, mixing cup, and ACD-A anticoagulant.
  • Small Volume Bone Marrow Aspiration Kit Bone marrow aspiration kit designed for small volume collection, including seven 10 mL syringes and ACD-A anticoagulant.
  • Solum Flow Injectable bone void filler composed of an equal ratio of porous hydroxyapatite granules and porcine gelatin, combined at a 1:1 volume ratio with biological fluid, with viscosity that allows easy injection from a needle.
  • Solum IV Synthetic extracellular matrix biomaterial with an interconnected pore architecture that supports cell adhesion, migration, and proliferation; when combined with bone marrow aspirate, forms a moldable 3D structure that acts as an in vivo bioreactor for bone growth.
  • VisuALIF Two-piece modular lumbar interbody fusion device with modular plating options, anterior open face PEEK component, radiolucent and biocompatible design with radiopaque tantalum markers, and patented design for maximum graft placement.
  • IN:C2 Two-piece modular cervical interbody fusion device with modular plating options, multiple screw placement and trajectory choices, and a locking snap-on face plate.
  • Corticalink System Spinal fixation system featuring Quadlead thread design for optimal stability, with self-tapping and self-starting screws, available in 5.5 Corticalink Open System, 5.0 MIS Corticalink, and 5.0 Midline Corticalink variants.
  • Facet Link Mini Facet joint stabilization system that provides robust spinal support and stability through a minimally invasive trans-articular screw approach.
  • Cimplicity Cervical interbody spacer made of biocompatible, radiolucent polyether ether ketone (PEEK) with a large graft area designed to maximize fusion potential.

Quantifiable outcome

  • The Hernigou aspiration method (basis for Cell Probe 360) obtains 300% more mesenchymal stem cells than traditional aspiration techniques
  • +3 more outcomes

Companies that use Celling Biosciences

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles5 records

Celling Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Celling Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • ThermiGencoreStrategic or Co-development Partner · 1 January 2019Celling Biosciences acquired ThermiGen in 2019, expanding into women's health and skin aesthetics markets. ThermiGen is known for its flagship product ThermiRF, which uses temperature to guide non-invasive and minimally-invasive procedures.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Celling Biosciences competitors and assessment

Company assessment

Direct peers

  • SpineSmith Partners: SpineSmith is a partner that has co-developed spinal hardware products with Celling and operates directly in the same spinal fusion and biologics segment as Celling's VisuALIF, IN:C2, Corticalink, and Cimplicity devices.
  • Emcyte Corporation: Emcyte is a direct competitor in point-of-care autologous PRP and bone marrow concentration systems, offering devices such as the Angel Concentrated Platelet Rich Plasma system that compete head-to-head with Celling's ART PRP and ART BMC families.
  • Isto Biologics: Isto Biologics develops autologous and allogeneic orthobiologic solutions including bone marrow concentration devices and bone graft substitutes, directly overlapping with Celling's ART BMC systems and Solum bone void filler products.

Emerging players

  • Regenexx: Regenexx is a regenerative medicine network that delivers autologous cell therapy procedures, including bone marrow concentrate treatments, to patients via affiliated physicians — directly comparable to Celling's clinical use cases in orthopedics and spine.
  • LifeNet Health: LifeNet Health is a regenerative medicine organization offering allograft and cellular therapies used in orthopedics, spine, and wound care — comparable to Celling's regenerative and bone void filler portfolio, though with a different sourcing and distribution model.
  • Cesca Therapeutics: Cesca Therapeutics develops autologous cell-based therapies and point-of-care cell processing technologies, making it a comparable emerging player in the autologous regenerative medicine category alongside Celling.

Broad incumbents

  • Terumo BCT: Terumo BCT is a leading cell and blood component processing technology provider. While focused on apheresis and higher-volume cell processing, its technology and commercial reach overlap with Celling's point-of-care concentration space.
  • Stryker: Stryker is a large diversified medtech player with deep orthopedic, spine, and surgical hardware franchises that overlap with Celling's spinal hardware (LinkSpine) and broader orthopedic cell therapy customers.
  • Zimmer Biomet: Zimmer Biomet operates broadly across orthopedics and sports medicine and has invested in regenerative and autologous biologic offerings, making it a broad incumbent comparable to Celling's orthopedic and spine regenerative portfolio.
  • Arthrex: Arthrex is a broad incumbent in orthopedic devices and biologics, offering PRP/BMAC preparation systems used across sports medicine, orthopedics, and spine — competing with Celling across multiple of the same specialties but as part of a much larger portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Celling Biosciences social profiles

Digital presence

Celling Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celling Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

Celling Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Celling Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celling Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celling Biosciences

What does Celling Biosciences do?

Celling Biosciences designs, manufactures, and sells point-of-care medical devices and consumables for autologous cellular therapy. Its core offering is the ART (Autologous Regenerative Therapies) family of bone marrow and platelet concentration systems, supplemented by bone marrow aspiration kits, Cell Probe 360 needles, Solum injectable bone void fillers, and a line of spinal hardware implants, all sold to physicians and healthcare providers.

Is Celling Biosciences a public or private company?

Celling Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Celling Biosciences founded?

Celling Biosciences was founded in 2005. It employs 11 to 50 people.

Where is Celling Biosciences based?

Celling Biosciences is headquartered in Austin, United States, in the North America region.

How does Celling Biosciences make money?

One revenue line is on record: medical Device and Consumable Sales.

Who are Celling Biosciences's main competitors?

Direct peers on record are SpineSmith Partners, Emcyte Corporation and Isto Biologics. Emerging players are Regenexx, LifeNet Health and Cesca Therapeutics. Broad incumbents are Terumo BCT, Stryker, Zimmer Biomet and Arthrex.

Does Celling Biosciences have an API?

No public API is recorded for Celling Biosciences.

What industry is Celling Biosciences in?

Celling Biosciences's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 33911 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCelling Spine Acquires Assets of Link Spine to Further Develop and Promote a Cell Centric Spine PlatformCelling Spine, a subsidiary of Celling Biosciences, has acquired all assets from Link Spine, a subsidiary of Germany-based Link Orthopedics. This acquisition allows Celling to integrate Link's spinal fusion technology with its own cell-based biologics to develop a comprehensive spine platform. The move is intended to accelerate Celling's growth strategy in the spine market by offering minimally invasive surgical options.PR NewswireCelling Biosciences, a pioneer in cellular therapy, acquires rights to ThermiGenCelling Biosciences acquired the assets and stock of ThermiGen, the aesthetic device division of Almirall, to expand its portfolio into women's health and aesthetics markets. The acquisition includes ThermiGen's radiofrequency-based devices, which generated $18 million in net sales in 2018 and have over 2,000 users. Celling intends to integrate these systems with its autologous cell therapy technology to develop new treatments for regenerative medicine.PR NewswireCelling Biosciences Executes Exclusive License with RxBIO Corp. to Launch Proprietary Stem Cell Technology in CanadaCelling Biosciences has entered into an exclusive license agreement with RxBIO Corp. to launch its proprietary autologous stem cell therapy technology in the Canadian market. This partnership leverages RxBIO's distribution infrastructure to provide physicians with regenerative treatment options aimed at preventative care and minimizing surgical interventions.PR NewswireCelling Biosciences Opens International Office in BrazilCelling Biosciences, a point-of-care cell therapy company headquartered in Austin, Texas, announced the opening of an international office in Curitiba, Brazil. The company views Brazil as one of the largest medical markets globally and expects the expansion to accelerate cell therapy adoption across South America, complementing its growing sales operations in Mexico. The Brazil office will initially target orthopedics, spine, pain management, and cosmesis/aesthetics segments.PR NewswireThe ART BMC System by Celling Biosciences Is Revolutionizing the Practice of Cell TherapyCelling Biosciences announced the launch of its ART BMC bone marrow concentration system, a point-of-care medical device designed to concentrate autologous bone marrow aspirate in 15 minutes. The system uses a dual capture technology that allows users to selectively deconstruct the stratified bone marrow stack to optimize the composition of the final preparation. This appears to be a product announcement press release describing the technical capabilities of the device without reporting any commercial outcomes or market impact.GlobeNewswireAmedica and Celling Biosciences to Collaborate on Biologically Enhanced Spinal Fusion DevicesAmedica and Celling Biosciences announced a collaboration to develop biologically enhanced spinal fusion implants. In vivo research showed Amedica's silicon nitride achieved five times greater mesenchymal stem cell adhesion than PEEK. The partners plan to translate findings into clinical trials for spinal and orthopedic applications.